WALTHAM, Mass., March 08, 2019 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) announced today topline results from PROLONG (Progestin’s Role in Optimizing Neonatal Gestation), a ...
Company Announces Collaboration With NurseWise(R) to Help Enhance Adherence to Makena(R) (hydroxyprogesterone caproate injection) Therapy WALTHAM, Mass., May 20, 2015 (GLOBE NEWSWIRE) -- AMAG ...
pregnant pregnancy Hydroxyprogesterone Caproate is used to lower the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth. American ...
In singleton gestations, 17 alpha-hydroxyprogesterone caproate (17P) has been shown to reduce the rate of recurrent preterm birth. This study was undertaken to evaluate whether 17P would reduce the ...
WALTHAM, Mass., June 26, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that the U.S. Food and Drug Administration (FDA) accepted the supplemental new drug ...
Please provide your email address to receive an email when new articles are posted on . Covis Pharma will voluntarily withdraw its preterm birth prevention drug Makena from the market. An FDA advisory ...
March 30, 2011 — Pharmacies can continue to compound generic hydroxyprogesterone caproate for reducing the risk for preterm delivery despite warnings from KV Pharmaceutical — which sells a costly, ...
The European rebuke comes after Covis’ hydroxyprogesterone caproate injection, known as Makena, suffered a similar fate in the U.S. last spring. (Melpomenem/Getty) Following a controversy over Covis’ ...
WALTHAM, Mass., Oct. 05, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) announced today that it received a notice from the U.S. Food and Drug Administration (FDA) that the FDA is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results